GSTT1 as a prognosticator for recurrence and progression in patients with non-muscle-invasive bladder cancer

Disease Markers

Volumn 29, Issue 2, 2010, Pages 81-87

  Ha, Yun Sok ^a   Yan, Chunri ^a,b   Lym, Min Su ^a,b   Jeong, Pildu ^a   Kim, Won Tae ^a   Kim, Yong June ^a,b   Yun, Seok Joong ^a   Lee, Sang Cheol ^a   Moon, Sung Kwon ^c   Choi, Yung Hyun ^d   Kim, Wun Jae ^a,b  

^a Chungbuk National University College of Medicine   (South Korea)

^b Chungbuk National University   (South Korea)

^c Chungju National University   (South Korea)

^d Dong Eui University   (South Korea)

Author keywords

biological tumor markers; polymorphism; prognosis; Urinary bladder neoplasms

Indexed keywords

GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; GENE DELETION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 78649515411     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2010-0729     Document Type: Article

References (30)

1. W.J.Kim, S. Park and Y.J.Kim, Biomarkers in bladder cancer: present status and perspectives, Biomark Insights 2 (2007), 95-105.
2. L.S.Borden Jr, P.E. Clark andM.C.Hall, Bladder cancer, Curr Opin Oncol 15 (2003), 227-233.
3. T.T.Wu, J.H. Chen, Y.H. Lee et al., The role of bcl2, p53, and ki67 index in predicting tumor recurrence for lowgrade superficial transitional cell bladder carcinoma, J Urol 163 (2000), 758-760.
4. M.Babjuk,W.Oosterlinck, R. Sylvester et al., EAUguidelines on nonmuscleinvasive urothelial carcinoma of the bladder, Eur Urol 54 (2008), 303-314.
5. G.R. Howe, J.D. Burch, A.B. Miller et al., Tobacco use, occupation, coffee, various nutrients, and bladder cancer, J Natl Cancer Inst 64 (1980), 701-713.
6. D.A. Bell, J.A. Taylor, D.F. Paulson et al., Genetic risk and carcinogen exposure: a common inherited defect of the carcinogenmetabolism gene glutathione StransferaseM1 (GSTM1) that increases susceptibility to bladder cancer, JNatl Cancer Inst 85 (1993), 1159-1164.
7. Y. Hirao, W.J. Kim and K. Fujimoto, Environmental factors promoting bladder cancer, Curr Opin Urol 19 (2009), 494-499.
8. T. Katoh, H. Inatomi, H. Kim et al., Effects of glutathione Stransferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk, Cancer Lett 132 (1998), 147-152.
9. W.J. Kim, H.L. Lee, S.C. Lee et al., Polymorphisms of Nacetyltransferase 2, glutathione Stransferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis, J Urol 164 (2000), 209-213.
10. J. Brockmoller, I. Cascorbi, R. Kerb et al., Combined analysis of inherited polymorphisms in arylamine Nacetyltransferase 2, glutathione Stransferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk, Cancer Res 56 (1996), 3915-3925.
11. W.J. Kim, H. Kim, C.H. Kim et al., GSTT1null genotype is a protective factor against bladder cancer, Urology 60 (2002), 913-918.
12. M. McGrath, D. Michaud and I. De Vivo, Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women, BMC Cancer 6 (2006), 239.
13. E.J. Kim, P. Jeong, C. Quan et al., Genotypes of TNFalpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer, Urology 65 (2005), 70-75.
14. D.K. Song, D.L.Xing, L.R. Zhang et al., Association ofNAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China, Cancer Detect Prev 32 (2009), 416-423.
15. F.L. Greene, The American Joint Committee on Cancer: updating the strategies in cancer staging, Bull Am Coll Surg 87 (2002), 13-15.
16. M.C. Hall, S.S. Chang, G. Dalbagni et al., Guideline for the management of non muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update, J Urol 178 (2007), 2314-2330.
17. H. Chen, D.P. Sandler, J.A. Taylor et al., Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect, Lancet 347 (1996), 295-297.
18. M. Kempkes, K. Golka, S. Reich et al., Glutathione Stransferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder, Arch Toxicol 71 (1996), 123-126.
19. R.J.Hung, P. Boffetta, P.Brennan et al., GST,NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a highrisk population, Int J Cancer 110 (2004), 598-604. (Pubitemid 38658026)
20. J. Salagovic, I. Kalina, V. Habalova et al., The role of human glutathione Stransferases M1 and T1 in individual susceptibility to bladder cancer, Physiol Res 48 (1999), 465-471.
21. X. Giannakopoulos, K. Charalabopoulos, D. Baltogiannis et al., The role of Nacetyltransferase2 and glutathione S transferase on the risk and aggressiveness of bladder cancer, Anticancer Res 22 (2002), 3801-3804.
22. S.J. Lee, S.H. Cho, S.K. Park et al., Combined effect of glutathione StransferaseM1 and T1 genotypes on bladder cancer risk, Cancer Lett 177 (2002), 173-179.
23. M. GarciaClosas, N. Malats, D. Silverman et al., NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and metaanalyses, Lancet 366 (2005), 649-659.
24. L.E. Johns and R.S. Houlston, Glutathione Stransferase mu1 (GSTM1) status and bladder cancer risk: a metaanalysis, Mutagenesis 15 (2000), 399-404.
25. L.S. Engel, E. Taioli, R. Pfeiffer et al., Pooled analysis and metaanalysis of glutathione Stransferase M1 and bladder cancer: a HuGE review, Am J Epidemiol 156 (2002), 95-109.
26. K. Golka, T. Schmidt, T. Seidel et al., The influence of polymorphisms of glutathione Stransferases M1 and M3 on the development of human urothelial cancer, J Toxicol Environ Health A 71 (2008), 881-886.
27. A. Castillejo, N. Rothman, C. MurtaNascimento et al., TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis, Int J Cancer 124 (2009), 608-613.
28. S.R. Pine, L.E.Mechanic, S. Ambs et al., Lung cancer survival and functional polymorphisms in MBL2, an innateimmunity gene, J Natl Cancer Inst 99 (2007), 1401-1409.
29. M.M. Gaudet, K. Hunter, P. Pharoah et al., Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis, Int J Cancer 124 (2009), 1716-1720.
30. R.C. Strange, P.W. Jones and A.A. Fryer, Glutathione Stransferase: genetics and role in toxicology, Toxicol Lett 112- 113 (2000), 357-363.